explore -WSS

explore

author：Wikipedia 2025-08-04 03:43:34 - browse：5971

Sen. Bernie Sanders, I-Vt., chairman of the Senate Health, Education, Labor, and Pensions Committee listens during a hearing on Capitol Hill in Washington – politics and policy coverage from STAT — Senate health committee Chair Bernie Sanders (I-Vt.) wants to reward new medicines with prize money. Jose Luis Magana/AP

WASHINGTON — Sen. Bernie Sanders (I-Vt.) will finally get a study of his proposal to do away with drug patents and other intellectual property protections in favor of rewarding inventions with prize money. Sanders has been pushing the prize approach since he was a House representative, many years ago.

The measure directing the National Academies of Sciences, Engineering and Medicine to study the idea was added to the Pandemic All-Hazards and Preparedness Act a day before Sander’s health committee passed the bill. Three Republicans voted against the overall bill, which renews several federal biodefense and pandemic-preparedness programs.

Though Democrats last year passed historic legislation to let Medicare negotiate drug prices and cap seniors’ annual out-of-pocket drug costs, Sanders is demanding more drug price controls. He is delaying President Biden’s pick for running the National Institutes of Health until the president releases a plan to control drug prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Readout Newsletter: Bayer study halts, Carmot to IPO, and more

leisure time

WSS

Iowa House, Senate pass 6

Leqembi, other new Alzheimer’s drugs require better biomarkers

A new study sees potential in DNA sequencing of infants

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Ransomware attacks on hospitals: Study outlines patient impact

Biden launches a new push to limit health care costs

focus

explore

focus

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Continuity nursing helped my family in our darkest PICU moments

Beach reads and more: STAT's 2023 summer book list

Drug repurposing or repositioning? The language matters

It's time to get medical device identifiers over the finish line

ChatGPT in medicine: STAT answers readers' burning questions

Oak trusses raised to roof of fire

Walensky prepares to leave CDC — and Congress — behind

Leqembi, other new Alzheimer’s drugs require better biomarkers

focus

NIH fellows want a pay raise. Will that mean less money for grants?

Why medical students are struggling with mental health

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Living with Fabry disease, a condition that causes chronic pain

Childhood cancer progress stalls for Black, Hispanic kids: Report

FDA's Woodcock to retire early next year

focus

explore

leisure time

hotspot